We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Advanced therapy of overweight or obese polycystic ovary syndrome: a prospective study.
- Authors
Min Min; Xiangyan Ruan; Mueck, Alfred O.
- Abstract
Objective: To investigate the effects of orlistat combined with drospirenone/ethinylestradiol tablets (DRSP/EE) on anthropometric indices, sexual hormones, hepatorenal function parameters of overweight or obese patients with polycystic ovary syndrome (PCOS). Methods: 75 overweight or obese PCOS patients [body mass index (BMI) ≥ 24 kg/m 2 ] were recruited within the Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, from April 2019 to January 2020, for a prospective, randomized, open-labelled comparing study. They were numbered one by one according to the order of recruitement and randomly divided into two groups, group 1 included 50 patients, orlistat plus DRSP/EE; group 2 included 25 patients treated with DRSP/EE alone. Both groups got the same comprehensive intervention in terms of individualized, standardized managment and monitoring of life-style like diet and exercise. The changes of anthropometric indices, sexual hormones, hepatorenal function parameters before and after three months of treatment in the two groups were compared . Results: After three months of treatment, body weight, waist circumference (WC), hip circumference (HC) and BMI of both groups were significantly decreased ( P < 0.05). The decrease of body weight, WC, HC and BMI in group 1 was significantly greater than those in group 2 ( P < 0.05). Free testosterone and sex hormone–binding globulin in both groups were significantly changed ( P < 0.05). There was no significant difference in the hepatorenal function parameters between the two groups after three months treatment ( P > 0.05). Conclusion: To our knowledge our study is the first to investigate the effects of orlistat combined with DRSP/EE in overweight or obese PCOS patients comparing with the effect of using DRSP/EE alone. Orlistat combined with DRSP/EE was better than use DRSP/EE alone in getting weight loss, which provides an evidence for the choice of rational drug use in clinical practice.
- Subjects
THERAPEUTIC use of estriol; STEROID drugs; OBESITY; DRUG efficacy; LIFESTYLES; POLYCYSTIC ovary syndrome; COMBINATION drug therapy; BODY weight; ANTHROPOMETRY; TESTOSTERONE; DIET; TREATMENT effectiveness; RANDOMIZED controlled trials; PRE-tests &; post-tests; COMPARATIVE studies; T-test (Statistics); SEX hormones; EXERCISE; WAIST circumference; DESCRIPTIVE statistics; RESEARCH funding; ORLISTAT; BODY mass index; STATISTICAL sampling; DATA analysis software; LONGITUDINAL method; EVALUATION
- Publication
Global Health Journal, 2022, Vol 6, Issue 2, p75
- ISSN
2096-3947
- Publication type
Article
- DOI
10.1016/j.glohj.2022.04.004